May 28, 2025 · Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.. If you have the …

Aug 5, 2025 · Ribociclib, palbociclib, and abemaciclib have revolutionized ER+ breast cancer therapeutics 4. However, most patients eventually develop resistance and progress after several …

Jul 1, 2025 · Here, we carried out a head-to-head effectiveness comparison of first-line palbociclib, ribociclib and abemaciclib, each used in combination with ET, in the context of the real-world, …

Oct 2, 2023 · Palbociclib-resistant breast cancers respond to abemaciclib and express pathway-specific signatures of sensitivity, providing a biomarker-driven therapeutic option for patients with metastatic …

FDA is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the ...

Conclusion: This study presents a comparison of the real-world efficacy between three CDK4/6i widely used in the Chinese population. Palbociclib, abemaciclib, and dalpiciclib demonstrated comparable …

5 days ago · CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib have rapidly become an established oral treatment for patients with ER+, HER2− locally advanced or metastatic breast …

Aug 31, 2023 · However, definitive investigations of the comparative efficacy and safety of different treatment combinations involving CDK4/6 inhibitors (abemaciclib, palbociclib, and ribociclib) and …

Apr 7, 2025 · However, the efficacy of palbociclib, ribociclib and abemaciclib has not been directly compared in large clinical studies. Indeed, most published real-world studies evaluated the …

In the first-line treatment of hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC), the comparative effectiveness of different cyclin-dependent kinase 4/6 inhibitors …